Huang Shanzhou, Ma Zuyi, Sun Chengjun, Zhou Qi, Li Zhenchong, Wang Shujie, Yan Qian, Liu Chunsheng, Hou Baohua, Zhang Chuanzhao
Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
South China University of Technology School of Medicine, Guangzhou 51000, China.
J Mater Chem B. 2022 Apr 13;10(15):2828-2843. doi: 10.1039/d2tb00044j.
Multi-drug resistance (MDR) is a complicated cellular defense mechanism for tumor cells to resist chemotherapy drugs, which is also the main cause of chemotherapy failure. In this study, a local injectable hydrogel delivery system was used to construct an on-demand sustained-release platform with the advantages of chemotherapy, photothermal therapy (PTT), and magnetic resonance imaging (MRI). It could achieve synergistic chemo-photothermal therapy and real-time evaluation of the therapeutic effects ( MRI) for MDR hepatocellular carcinoma (HCC). Furthermore, after a single administration, the prepared hydrogel with a theranostic nanoprobe could release the therapeutic agents on demand for up to 14 d. Firstly, doxorubicin (DOX) and gold-manganese oxide (Au-MnO) nanoparticles (NPs) were incorporated into liposome-based self-assembled micelles, then loaded into the thermosensitive hydrogel (F127) to form DOX@Au-MnO-L NPs/F127 hydrogel (DAML/H). The prepared NP complex showed a spherical morphology with a narrow size distribution. The prepared hydrogel drug delivery system had injectable properties and stable photothermal conversion. Both the DOX@Au-MnO-L NPs and DAML/H showed controlled drug release under near infrared (NIR) laser irradiation. The MRI studies indicated that the prepared DAML/H had a high relaxation rate (14.38 mM s) and good MRI scanning sensitivity conditions. The and results suggested the synergistic chemo-photothermal therapy of DAML/H with NIR irradiation (808 nm, 1 W cm, 10 min) improved the antitumor efficacy for MDR HCC. The retention experiment of Au in tumors indicated that the prepared hydrogel drug delivery system (DAML/H) had a good ability to retain Au in the tumor for a long time (at least 14 d). The western blotting results revealed that DAML/H with laser treatment could effectively downregulate P-glycoprotein (P-gp), p53 and antiapoptotic protein (Bcl-2), whereas the expression level of proapoptotic protein (Bax) and caspase-3 were increased. Therefore, DAML/H could serve as a promising synergistic chemo-photothermal therapy for MDR HCC, and a single administration might achieve long-term (14 d), on-demand, sustained-release treatment of tumors.
多药耐药(MDR)是肿瘤细胞抵抗化疗药物的一种复杂细胞防御机制,也是化疗失败的主要原因。在本研究中,使用局部可注射水凝胶递送系统构建了一个具有化疗、光热疗法(PTT)和磁共振成像(MRI)优势的按需持续释放平台。它可以实现对多药耐药肝细胞癌(HCC)的协同化疗-光热疗法以及治疗效果的实时评估(MRI)。此外,单次给药后,制备的带有诊疗纳米探针的水凝胶可按需释放治疗剂长达14天。首先,将阿霉素(DOX)和金-氧化锰(Au-MnO)纳米颗粒(NPs)掺入基于脂质体的自组装胶束中,然后加载到热敏水凝胶(F127)中,形成DOX@Au-MnO-L NPs/F127水凝胶(DAML/H)。制备的纳米颗粒复合物呈球形形态,粒径分布窄。制备的水凝胶药物递送系统具有可注射性和稳定的光热转换性能。DOX@Au-MnO-L NPs和DAML/H在近红外(NIR)激光照射下均显示出可控的药物释放。MRI研究表明,制备的DAML/H具有高弛豫率(14.38 mM s)和良好的MRI扫描灵敏度条件。 和 结果表明,DAML/H在NIR照射(808 nm,1 W cm,10 min)下的协同化疗-光热疗法提高了对多药耐药HCC的抗肿瘤疗效。Au在肿瘤中的保留实验表明,制备的水凝胶药物递送系统(DAML/H)具有良好的长时间(至少14天)在肿瘤中保留Au的能力。蛋白质印迹结果显示,经激光处理的DAML/H可有效下调P-糖蛋白(P-gp)、p53和抗凋亡蛋白(Bcl-2),而促凋亡蛋白(Bax)和半胱天冬酶-3的表达水平则升高。因此,DAML/H可作为一种有前景的针对多药耐药HCC的协同化疗-光热疗法,单次给药可能实现对肿瘤的长期(14天)、按需、持续释放治疗。